HighVista Strategies LLC Buys 24,800 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

HighVista Strategies LLC boosted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 21.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 138,350 shares of the company’s stock after acquiring an additional 24,800 shares during the period. HighVista Strategies LLC owned 0.20% of Perspective Therapeutics worth $1,847,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in CATX. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $57,000. US Bancorp DE increased its position in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the period. Victory Capital Management Inc. bought a new position in shares of Perspective Therapeutics in the second quarter worth $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics in the second quarter worth $118,000. Finally, Intech Investment Management LLC bought a new position in Perspective Therapeutics in the third quarter valued at about $137,000. Institutional investors own 54.66% of the company’s stock.

Insider Buying and Selling

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt purchased 12,829 shares of the company’s stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the purchase, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. This represents a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Johan M. Spoor purchased 14,500 shares of the company’s stock in a transaction on Monday, November 25th. The stock was acquired at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the purchase, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 33,595 shares of company stock valued at $126,625 over the last ninety days. 3.52% of the stock is owned by company insiders.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $4.11 on Tuesday. The business’s 50-day moving average price is $10.44 and its 200-day moving average price is $12.21. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Truist Financial assumed coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. UBS Group assumed coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Finally, Oppenheimer decreased their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Perspective Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.